Highest-materiality recent filing
SenesTech Q1 revenue +2% to $493K; record gross margin 68.6%; direct-to-consumer up 42%
Net loss $2.1M vs $1.7M YoY; includes $443K severance/legal costs; adjusted EBITDA loss $1.6M.
SenesTech appoints Michael Edell as President and CEO, succeeding Joel L. Fruendt
Michael Edell appointed President and CEO effective May 6, 2026, succeeding Joel L. Fruendt.
SenesTech reports FY2025 revenue up 20% to $2.2M; net loss $6.4M; CEO transition started
Full-year 2025 revenue $2.2M (+20% YoY); gross profit margin improved to 62.5% from 54.1%.
SenesTech CEO Joel Fruendt to retire; Jamie Bechtel appointed Interim Executive Chair
CEO Joel L. Fruendt retiring effective earlier of June 30, 2026 or successor appointment.
SenesTech CEO Joel Fruendt to retire by June 30, 2026; Jamie Bechtel named Interim Executive Chair
President and CEO Joel L. Fruendt notified retirement effective earlier of June 30, 2026 or date successor appointed.
SenesTech Q3 2025 revenue $690k (record), net loss improves to $1.3M; Evolve up 77% YoY
Revenue $690k, +43% YoY, a record; gross margin 62.8% in line with expectations.
SenesTech Q2 record revenue $625K (+36% YoY); Evolve sales up 94% YoY
Revenue $625K (record), +36% YoY; Evolve Rodent Birth Control sales +94% YoY, now 83% of total revenue.
SenesTech raises $6.3M via warrant exercise and new warrant issuance
Holders exercise existing warrants for 1,458,872 shares at $4.15, generating $6.3M gross.
SenesTech raises $4.4M via warrant exercise, issues new warrants at $4.15
Gross proceeds of ~$4.4M from cash exercise of 1,458,872 existing warrants at $2.90/share.
SenesTech Q1 revenue $485K (+17% YoY), record gross margin 64.5%, net loss $1.7M
Evolve product sales grew 40% YoY, now 79% of total revenue.
SenesTech reports Q4 revenue up 70% YoY, gross margin 61%, launches $2M cost reduction plan
Q4 revenue $501K, +70% YoY; gross margin 60.9% (vs 43.7%); net loss $1.3M (vs $1.7M).
SenesTech enters warrant exercise agreements for ~$1.1M gross proceeds and issues new warrants
Existing warrants for 374,718 shares exercised at reduced price of $2.90/share (from $4.35); gross proceeds $1,086,682.
SenesTech Q3 2024 revenue up 51% YTD; gross margin 65% record; operating expenses down 12%
YTD revenue $1.4M, +51% YoY; Q3 gross margin 65% vs 49% in prior year.
SenesTech enters inducement letter to raise ~$2.33M via warrant exercise at $4.60/share
Inducement letter signed Aug 22, 2024; holders exercise 505,502 shares at reduced price $4.60, gross proceeds $2,325,306.
Revenue $459k in Q2 2024, up 50% YoY; H1 revenue $874k, up 62% YoY.
SenesTech executes 1:10 reverse stock split, effective July 24, 2024
Reverse split ratio of 1:10 approved by board on July 11; effective 4:01 p.m. ET July 24, 2024.
SenesTech shareholders approve reverse stock split and equity plan share increase
Reverse stock split approved at ratio between 1:2 and 1:20; board to set exact ratio.
SenesTech Q1 revenue $415K record, up 78% YoY; Evolve drives >50% of sales
Q1 2024 revenue $415,000, up 78% from $233,000 in Q1 2023; record quarterly revenue.
SenesTech receives extended deadline to Aug 19, 2024 for Nasdaq bid price compliance
Failed to regain minimum $1.00 bid price by Feb 21, 2024; Nasdaq grants second 180-day period.
SenesTech FY2023 revenue up 17% to $1.2M; YTD 2024 revenue up >80% on Evolve launch
FY2023 revenue of $1.2M (up 17% from $1.0M in 2022); net loss improved to $7.7M from $9.7M.
SenesTech closes $5M public offering of common stock and warrants
Raised ~$5M gross from offering of 3,846,154 units (common stock or pre-funded warrants) at $1.30/unit, plus Series D and E warrants.
SenesTech gets Nasdaq delisting notice for insufficient publicly held shares after reverse split
Post 1-for-12 reverse split, common shares outstanding reduced to 492,293, below the 500,000 minimum.
SenesTech Q3 revenue up 44% to $360K, net loss improves $700K; Evolve Soft Bait launch imminent
Revenue of $360K in Q3 2023, up 44% from $250K in Q3 2022.
SenesTech receives Nasdaq bid price deficiency notice; 180-day cure period
Nasdaq notified SenesTech on Aug 25, 2023 that bid price closed below $1.00 for 30 consecutive business days.
SenesTech to receive ~$2.1M from warrant exercise; issues new warrants for 5.9M shares
Holder exercises existing warrants for 2,934,575 shares at reduced price $0.7202/share; gross proceeds $2,113,480.92.
SenesTech Q2 2023 revenue $305K, net loss $2.0M; July sales up 126% YoY
Q2 revenue $305K vs $277K YoY; gross profit margin 46% (51% excl. one-time write-downs).
SenesTech raises $1.5M in registered direct offering of 857,146 shares at $1.75 plus warrants
Sold 857,146 shares and Series C warrants for gross proceeds of ~$1.5M; offering closed April 12, 2023.
SenesTech FY2022 product sales break $1M, up 77% YoY; net loss $9.7M
Product sales $1.0M in 2022, up 77% vs 2021; e-commerce was 46% of sales.
SenesTech closes $5M public offering of stock and warrants; net proceeds ~$4.25M
Offered 1,428,572 shares (or pre-funded warrants) plus Series A and B warrants at $3.50/unit, gross $5.0M.
SenesTech effects 1-for-20 reverse stock split; shares reduce to ~610,648
Reverse stock split ratio of 1:20 approved by board; effective 11:59 p.m. ET on Nov 15, 2022.
SenesTech Q3 product sales +57% YoY; appoints Joel Fruendt as CEO
Product sales rose 57% YoY to ~$250k total revenue; gross margin improved to 52% from 48%.
succeeding Mr. Joel L. Fruendt, the current President and Chief Executive Officer of the Company.
On May 6, 2026, Mr. Edell was also appointed as a member of the Board, and will serve as a Class III director of the Board
appointed Michael Edell as the Company’s President and Chief Executive Officer
On January 8, 2025, our Board of Directors (the “Board”) authorized an increase in the size of the Board to six members and appointed Joshua M. Moss to serve on the Board as an independent director.
On April 20, 2023, Nicole Williams’ employment with our company terminated.
On February 15, 2023, we appointed Nicole Williams as Chief Revenue Officer.
Mr. Siegel also resigned from his position as a director of our company effective as of December 31, 2022
In connection with the previously announced retirement of Kenneth Siegel, our former Chief Executive Officer
and is expected to retire as a director on December 31, 2022.
On November 14, 2022, Joel Fruendt was appointed as Chief Executive Officer of our company, effective as of November 15, 2022
Mr. Fruendt was also appointed as a member of our Board of Directors, effective as of the Commencement Date.
Mr. Siegel’s retirement as our Chief Executive Officer will be effective November 15, 2022.
Max materiality 0.80 · Median 0.60 · Most common event other_material